KG
BMRN icon

Kilter Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kilter Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$916 Buy
+16
New +$876 ﹤0.01% 1290

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Kilter Group's BMRN Position: Q2 2026 in Review

Kilter Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 16 shares worth $916. The stake represents ﹤0.01% of the portfolio and ranks #1290 among its holdings.

561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Kilter Group held 16 shares of BioMarin Pharmaceuticals worth $916 as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Kilter Group position in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #1290 holding.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.